# A Study of Galcanezumab (LY2951742) in Adult Participants With Episodic Migraine

> **NCT05127486** · PHASE4 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 580 (actual)

## Conditions studied

- Migraine
- Episodic Migraine

## Interventions

- **DRUG:** Galcanezumab
- **DRUG:** Rimegepant
- **DRUG:** Placebo
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05127486
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-12-06
- **Primary completion:** 2023-05-23
- **Final completion:** 2023-05-23
- **Target enrollment:** 580 (ACTUAL)
- **Last updated:** 2024-06-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05127486

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05127486, "A Study of Galcanezumab (LY2951742) in Adult Participants With Episodic Migraine". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05127486. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*